ArticleEuropean journal of clinical pharmacology2025

Post-marketing safety signals of imatinib: pharmacovigilance insights from the FDA Adverse Event Reporting System (FAERS) and implications for clinical practice.

Tianqin Xia et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.